)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Nurix Therapeutics
Nurix Therapeutics (NRIX) investor relations material
Nurix Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary28 Jan, 2026
Executive summary
Initiated pivotal DAYBreak Phase 2 study for bexobrutideg in relapsed/refractory CLL, with regulatory alignment on dose selection and strong Phase 1 data showing 83% ORR and 22.1 months PFS.
Presented new clinical and preclinical data across pipeline, including promising results for bexobrutideg in Waldenström macroglobulinemia and IRAK4 degrader GS-6791 in collaboration with Gilead.
Strengthened balance sheet with $250M equity offering, ending the year with $592.9M in cash and marketable securities.
Appointed Roger Dansey, M.D., to the Board, adding oncology expertise.
Financial highlights
Fiscal Q4 2025 revenue was $13.6M; full-year revenue was $84.0M, up from $54.5M in 2024, driven by $30M in Sanofi license extensions and milestone payments from Sanofi, Pfizer, and Gilead.
R&D expenses rose to $83.0M for Q4 and $316.9M for the year, reflecting increased clinical activity.
Net loss for Q4 was $78.2M ($0.82/share); full-year net loss was $264.5M ($3.05/share), compared to $193.6M ($2.88/share) in 2024.
Cash and marketable securities totaled $592.9M at year-end, down from $609.6M a year earlier.
Outlook and guidance
Ongoing enrollment in pivotal DAYBreak Phase 2 study for CLL, with plans to initiate a global Phase 3 confirmatory trial in 2026.
Continued advancement of bexobrutideg in autoimmune and inflammatory diseases, with Phase 1b and healthy volunteer studies underway.
Anticipated updates from collaborations with Gilead, Sanofi, and Pfizer, and further clinical milestones expected in 2026.
Bexobrutideg Phase 3 comparator rationale
Cash runway with current burn rate
IRAK4 degrader's competitive edge vs. bexobrutideg in autoimmune?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Nurix Therapeutics earnings date
Q1 20267 Apr, 2026
Nurix Therapeutics
Next Nurix Therapeutics earnings date
Q1 20267 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule and cell therapies. These therapies are designed to treat cancer and inflammatory diseases by modulating cellular protein levels. Nurix leverages its proprietary DELigase platform, which involves the use of E3 ligases within the ubiquitin-proteasome system, to either decrease or increase protein levels selectively. The company’s drug development strategy includes both targeted protein degraders and ligase inhibitors, addressing unmet medical needs in hematology-oncology, immuno-oncology, and inflammation. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage